Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

Saved in:
Bibliographic Details
Published inJournal of the International AIDS Society Vol. 13; no. S4; p. O51
Main Authors Eron, J, Livrozet, JM, Morlat, P, Lazzarin, A, Katlama, C, Hawkins, T, Fujiwara, T, Cuffe, R, Vavro, C, Santiago, J, Ait‐Khaled, M, Min, S, Yeo, JM
Format Journal Article
LanguageEnglish
Published Geneva The International AIDS Society 01.11.2010
John Wiley & Sons, Inc
BioMed Central Ltd
Subjects
Analysis
Antiretroviral drugs
Antiviral agents
Disease susceptibility
Dosage and administration
HIV infection
HIV testing
Human immunodeficiency virus
Integrase inhibitors
Oral Presentation
Prevention
Risk factors
Testing
Switzerland
Online AccessGet full text

Cover

More Information
Summary:7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:1758-2652
1758-2652
DOI:10.1186/1758-2652-13-S4-O51